Skip to main content

Corporate News

30 May 2024

REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications. BELTSVILLE, ...

17 May 2024

Hyderabad, India and Doha, Qatar – May 6, 2024 – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is excited to announce a new distributorship agreement with RISVI Trading W.L.L., a renowned trading ...

16 May 2024

REPROCELL is thrilled to share groundbreaking research facilitated by our StemRNA™ Clinical Seed iPSCs, a pivotal step forward in redefining women's healthcare. In tandem with our partner Gameto, a female-led biotechnology company, we provi...

14 May 2024

Glasgow, UK & Kaunas, Lithuania – REPROCELL, a leading player in the field of drug discovery, is thrilled to announce its strategic partnership with Nova Natura UAB, a prominent distributor specializing in laboratory instruments, reagents, ...

18 April 2024

REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for the generation of Human Induced Pluripotent Cells (hiPSC) in Beltsville for human therapeutic applications. REPROCELL has been producing clini...

08 February 2024

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...

31 January 2024

REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...

15 January 2024

SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...

15 December 2023

The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...

24 October 2023

On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from fresh human tissue “The purpose of this study...